SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    Roger B. Cohen, Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC), Cancer Treatment Reviews, 2014, 40, 4, 567

    CrossRef

  2. 2
    Yu Du, Noah D. Peyser, Jennifer R. Grandis, Integration of molecular targeted therapy with radiation in head and neck cancer, Pharmacology & Therapeutics, 2014, 142, 1, 88

    CrossRef

  3. 3
    Jae Won Chang, Chul-Ho Kim, Molecular Targeted Therapy of Head and Neck Cancer: Promising Molecular Targets of Post-Epidermal Growth Factor Receptor Era, Korean Journal of Otorhinolaryngology-Head and Neck Surgery, 2014, 57, 9, 575

    CrossRef

  4. 4
    Yaghoub Safdari, Masoumeh Khalili, Safar Farajnia, Mohammad Asgharzadeh, Yaghoub Yazdani, Mahnaz Sadeghi, Recent advances in head and neck squamous cell carcinoma — A review, Clinical Biochemistry, 2014, 47, 13-14, 1195

    CrossRef

  5. 5
    Sandra Schmitz, Kie Kian Ang, Jan Vermorken, Robert Haddad, Carlos Suarez, Gregory T. Wolf, Marc Hamoir, Jean-Pascal Machiels, Targeted therapies for squamous cell carcinoma of the head and neck: Current knowledge and future directions, Cancer Treatment Reviews, 2014, 40, 3, 390

    CrossRef

  6. 6
    Jiezhong Chen, Aymen Elfiky, Mei Han, Chen Chen, M. Wasif Saif, The Role of Src in Colon Cancer and Its Therapeutic Implications, Clinical Colorectal Cancer, 2014, 13, 1, 5

    CrossRef

  7. 7
    K E Hayes, E L Walk, A G Ammer, L C Kelley, K H Martin, S A Weed, Ableson kinases negatively regulate invadopodia function and invasion in head and neck squamous cell carcinoma by inhibiting an HB-EGF autocrine loop, Oncogene, 2013, 32, 40, 4766

    CrossRef

  8. 8
    Yan Song, Xin Sun, Wei-Liang Bai, Wen-Yue Ji, Antitumor effects of Dasatinib on laryngeal squamous cell carcinoma in vivo and in vitro, European Archives of Oto-Rhino-Laryngology, 2013, 270, 4, 1397

    CrossRef

  9. 9
    Hanneke Stegeman, Johannes HAM Kaanders, Marieke MG Verheijen, Wenny JM Peeters, Deric L Wheeler, Mari Iida, Reidar Grénman, Albert J van der Kogel, Paul N Span, Johan Bussink, Combining radiotherapy with MEK1/2, STAT5 or STAT6 inhibition reduces survival of head and neck cancer lines, Molecular Cancer, 2013, 12, 1, 133

    CrossRef

  10. 10
    Hanneke Stegeman, Paul N. Span, Paul F.J.W. Rijken, Simone C. Cockx, Deric L. Wheeler, Mari Iida, Albert J. van der Kogel, Johannes H.A.M. Kaanders, Johan Bussink, Dasatinib Inhibits DNA Repair after Radiotherapy Specifically in pSFK-Expressing Tumor Areas in Head and Neck Xenograft Tumors, Translational Oncology, 2013, 6, 4, 413

    CrossRef

  11. 11
    Paolo Bossi, Laura Locati, Lisa Licitra, Emerging tyrosine kinase inhibitors for head and neck cancer, Expert Opinion on Emerging Drugs, 2013, 18, 4, 445

    CrossRef

  12. 12
    Pol Specenier, Jan B. Vermorken, Biologic Therapy in Head and Neck Cancer: A Road with Hurdles, ISRN Oncology, 2012, 2012, 1

    CrossRef

  13. 13
    T. Kurzweg, N. Möckelmann, S. Laban, R. Knecht, Current treatment options for recurrent/metastatic head and neck cancer: a post-ASCO 2011 update and review of last year’s literature, European Archives of Oto-Rhino-Laryngology, 2012, 269, 10, 2157

    CrossRef

  14. 14
    Uma Raju, Oliver Riesterer, Zhi-Qiang Wang, David P. Molkentine, Jessica M. Molkentine, Faye M. Johnson, Bonnie Glisson, Luka Milas, K. Kian Ang, Dasatinib, a multi-kinase inhibitor increased radiation sensitivity by interfering with nuclear localization of epidermal growth factor receptor and by blocking DNA repair pathways, Radiotherapy and Oncology, 2012, 105, 2, 241

    CrossRef

  15. 15
    Shyam D. Rao, Matthew G. Fury, David G. Pfister, Molecular-Targeted Therapies in Head and Neck Cancer, Seminars in Radiation Oncology, 2012, 22, 3, 207

    CrossRef

  16. 16
    Lokesh Nagaprashantha, Neha Vartak, Sangeeta Awasthi, Sanjay Awasthi, Sharad S. Singhal, Novel Anti-cancer Compounds for Developing Combinatorial Therapies to Target Anoikis-Resistant Tumors, Pharmaceutical Research, 2012, 29, 3, 621

    CrossRef

  17. 17
    Ranee Mehra, Ilya G. Serebriiskii, Roland L. Dunbrack, Matthew K. Robinson, Barbara Burtness, Erica A. Golemis, Protein-intrinsic and signaling network-based sources of resistance to EGFR- and ErbB family-targeted therapies in head and neck cancer, Drug Resistance Updates, 2011, 14, 6, 260

    CrossRef